Vertex Acquires Potential CF Therapy, CTP-656, a Deuterium-Modified Form of Kalydeco
Cystic Fibrosis, News
Vertex Pharmaceuticals has signed a $160 million purchase agreement to acquire CTP-656, a potential treatment for cystic fibrosis (CF), from Concert Pharmaceuticals. The agreement covers development and marketing rights worldwide. ... Read more